Jelena Karanović

Dr. Jelena Karanović

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2015 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
JKJelena Karanović
Jelena Karanović
SŠSaša Šviković
Saša Šviković
MPMaja Pantović
Maja Pantović
SDSvetlana Durica
Svetlana Durica
GBGoran Brajušković
Goran Brajušković
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic
Adenosine to inosine RNA editing, serotonin 2C receptor (HTR2C), and stressful life events (SLEs) have all been implicated in suicidal behaviour. We examined the main and moderating effects of RNA editing (ADAR, ADARB1) and HTR2C genes, childhood trauma (CT), recent SLEs and psychiatric disorders as contributors to suicide attempt (SA) vulnerability. Study included 165 suicide attempters and 188 suicide non-attempters, all diagnosed with one of major psychiatric disorders. CT and recent SLEs were assessed using Early Trauma Inventory-Self Report and List of Threatening Experiences Questionnaire, respectively. Selected ADAR and ADARB1 tag-variants, and HTR2C rs6318 were pre-screened for association with SA, while generalized linear models and backward selection were applied to identify individual and interacting SA risk factors. ADARB1 rs9983925 and rs4819035 and HTR2C rs6318 were associated with SA. The best minimal model found emotional abuse, recent SLEs, rs9983925 and rs6318 as independent SA risk factors, and general traumas as a factor moderating the effect of psychiatric disorders and emotional abuse. SA vulnerability in psychiatric patients is related to the joint effect of ADARB1 and HTR2C variants, the existing mood disorder and the cumulative exposures to a various childhood and recent stressful experiences.

13 January 2017 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
JKJelena Karanović
Jelena Karanović
MIMaja Ivković
Maja Ivković
VJVladimir M. Jovanović
Vladimir M. Jovanović
SŠSaša Šviković
Saša Šviković
MPMaja Pantović-Stefanović
Maja Pantović-Stefanović
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic

2 April 2016 in Suicide and Life-Threatening Behavior
Verified
Journal Article
Closed access
PDF file
JKJelena Karanović
Jelena Karanović
MIMaja Ivković
Maja Ivković
VJVladimir M. Jovanović
Vladimir M. Jovanović
MPMaja Pantović
Maja Pantović
NPNataša Pavlović‐Janković
Nataša Pavlović‐Janković
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic

25 May 2024 in Cells
Verified
Journal Article
Open access
PDF file
KZKristina Zdravkova
Kristina Zdravkova
OMOlja Mijanovic
Olja Mijanovic
Ana BrankovicAna Brankovic
Ana Brankovic
PIPolina M. Ilicheva
Polina M. Ilicheva
ASAleksandra Stankovski
Aleksandra Stankovski
Andrey A. Zamyatnin Jr.Andrey A. Zamyatnin Jr.
Andrey A. Zamyatnin Jr.
Cysteine cathepsins F and W are members of the papain-like cysteine protease family, which have distinct structural features and functional roles in various physiological and pathological processes. This review provides a comprehensive overview of the current understanding of the structure, biological functions, and pathological implications of cathepsins F and W. Beginning with an introduction to these proteases, we delve into their structural characteristics and elucidate their unique features that dictate their enzymatic activities and substrate specificity. We also explore the intricate involvement of cathepsins F and W in malignancies, highlighting their role as potential biomarkers and therapeutic targets in cancer progression. Furthermore, we discuss the emerging roles of these enzymes in immune response modulation and neurological disorders, shedding light on their implications in autoimmune and neurodegenerative diseases. Finally, we review the landscape of inhibitors targeting these proteases, highlighting their therapeutic potential and challenges in clinical translation. This review brings together the diverse facets of cysteine cathepsins F and W, providing insights into their roles in health and disease and guiding future investigations for therapeutic advances.


Verified
Journal Article
Open access
PDF file
MBMiloš Brkušanin
Miloš Brkušanin
NGNemanja Garai
Nemanja Garai
JKJelena Karanović
Jelena Karanović
TJTamara Sljivancanin Jakovljevic
Tamara Sljivancanin Jakovljevic
ADAleksandra Dimitrijević
Aleksandra Dimitrijević
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic
Innovative treatments for spinal muscular atrophy (SMA) yield the utmost advantages only within the presymptomatic phase, underlining the significance of newborn screening (NBS). We aimed to establish statewide NBS for SMA in Serbia. Our stepwise implementation process involved technical validation of a screening assay, collaboration with patient organizations and medical professionals, a feasibility study, and negotiation with public health representatives. Over 12,000 newborns were tested during the 17-month feasibility study, revealing two unrelated SMA infants and one older sibling. All three children received therapeutic interventions during the presymptomatic phase and have shown no signs of SMA. No false-negative results were found among the negative test results. As frontrunners in this field in Serbia, we established screening and diagnostic algorithms and follow-up protocols and raised awareness among stakeholders about the importance of early disease detection, leading to the incorporation of NBS for SMA into the national program on 15 September 2023. Since then, 54,393 newborns have been tested, identifying six SMA cases and enabling timely treatment. Our study demonstrates that effective collaborations between academia, non-profit organizations, and industry are crucial in bringing innovative healthcare initiatives to fruition, and highlights the potential of NBS to revolutionize healthcare outcomes for presymptomatic SMA infants and their families.